NTLA vs ZTS · rev $22.7M vs P/E 25, rev $2.47B
Intellia Therapeutics Inc (NTLA) versus Zoetis Inc (ZTS) — a side-by-side from cached financials, not a winner call.
Intellia Therapeutics Inc (NTLA) is a biotechnology company listed on US.
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported NTLA revenue for 2026-06-30 was $22.7M. Net income was -$202.9M. Revenue was up 50.9% from 2026-03-31 to 2026-06-30. NTLA currently screens at market cap $1.19B.
Latest reported ZTS revenue for 2026-06-30 was $2.47B. Net income was $691.0M. Revenue was up 9.1% from 2026-03-31 to 2026-06-30. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
NTLA currently screens at market cap $1.19B. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
Not investment advice. Open the NTLA and ZTS stock pages for the full models.
Not investment advice.